Paper Details

  1. Home
  2. Paper Details

Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.

Author: EastellR, McCloskeyE, PaggiosiM A, PeelN, WalshJ S

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effects of oral alendronate, ibandronate, and risedronate on bone health over 2 years. Ibandronate and alendronate were found to have a greater effect on the central skeleton (spine) than risedronate, while all three drugs had similar effects on the peripheral skeleton (hip). These findings suggest that ibandronate may be a more effective option for increasing bone density at the spine compared to risedronate.
Paper Details　
Original Abstract of the Article :
We compared the effects of oral alendronate, ibandronate and risedronate on the central and peripheral skeleton over 2 years. We report differences in effect on the central skeleton but not on the peripheral skeleton. Greater effects were observed for ibandronate (and alendronate) than risedronate a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00198-014-2817-z

データ提供：米国国立医学図書館（NLM）

Bone Health: Comparing the Effects of Bisphosphonate Therapies

Postmenopausal osteoporosis, a condition that weakens bones and increases fracture risk, is like a desert landscape – seemingly solid, but prone to erosion. This research compares the effects of three oral bisphosphonate therapies – alendronate, ibandronate, and risedronate – on bone density in postmenopausal women. The study, known as TRIO, followed participants for two years, measuring bone density changes in both the central and peripheral skeleton. This approach is like surveying a desert landscape to understand the impact of erosion on different areas.

A Tale of Two Skeletons

The researchers found that ibandronate and alendronate were more effective at increasing bone density in the spine compared to risedronate, although no significant differences were observed in the peripheral skeleton. This finding is like discovering that certain areas of a desert landscape are more vulnerable to erosion than others. It highlights the importance of considering individual bone density needs when selecting bisphosphonate therapy.

Strengthening Our Foundation

This research provides valuable insights into the different effects of bisphosphonate therapies on bone density. It’s like learning which desert plants are best suited for different types of soil. This knowledge can help doctors personalize treatment plans, promoting stronger bones and reducing fracture risk in postmenopausal women. It's like creating a more resilient desert landscape, capable of withstanding the forces of time and weathering.

Dr.Camel's Conclusion

This research, like a careful analysis of a desert landscape, reveals the unique effects of different bisphosphonate therapies on bone density. Understanding these differences, like identifying the most resilient desert plants, can help doctors personalize treatment plans and promote stronger bones. This research is a reminder that our skeletal health is as complex and diverse as a desert ecosystem, and it's crucial to understand these nuances for optimal care.
Date :
  1. Date Completed 2015-11-23
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

25074351

DOI: Digital Object Identifier

10.1007/s00198-014-2817-z

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.